Examination of some factors responsible for a food‐induced increase in absorption of atovaquone.
- 1 January 1994
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 37 (1) , 13-20
- https://doi.org/10.1111/j.1365-2125.1994.tb04232.x
Abstract
1. Atovaquone is a potent antiprotozoal slowly and irregularly absorbed after administration as tablets to fasting volunteers. A series of studies was performed to investigate the effects of food, bile and formulation on atovaquone absorption. 2. In 18 healthy male volunteers, a high-fat breakfast administered 45 min before 500 mg atovaquone as tablets increased AUC by 3.3-fold (95% CI 2.8-4.0) and Cmax 5.3-fold (4.3-6.6) compared with fasting. 3. The absorption of atovaquone from tablets was examined in 12 healthy male volunteers after an overnight fast, following toast alone, toast with 28 g butter (LOFAT), or toast with 56 g butter (HIFAT). Compared with absorption when fasted, toast had no significant effect but LOFAT increased AUC 3.0-fold (2.1-4.2) and Cmax 3.9-fold (2.6-5.8). HIFAT increased AUC 3.9-fold (2.7-5.5) and Cmax 5.6-fold (3.8-8.4). 4. The absorption of atovaquone was examined in nine healthy fasting male volunteers from tablets, an aqueous suspension, and an oily solution/suspension in miglyol (fractionated coconut oil). Compared with tablets, AUC following the aqueous suspension was increased 1.7-fold (1.0-2.7) and Cmax 2.4-fold (1.7-3.5). Following miglyol, AUC was increased to the same extent but Cmax was only increased 1.8-fold (1.2-2.6). 5. Atovaquone absorption was examined in eight healthy fasting male volunteers following an i.v. infusion of cholecystokinin octapeptide (CCK-OP) which decreased gallbladder volume by 82% (73%-90%) on occasion 1 or saline on occasion 2. AUC(0,12) was increased following CCK-OP by 1.6-fold (1.1-2.4) and Cmax by 1.5-fold (0.98-2.4).(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 21 references indexed in Scilit:
- Evaluation of the Effect of Drugs on the Cyst Form of Toxoplasma gondiiThe Journal of Infectious Diseases, 1991
- Safety and Pharmacokinetics of 566C80, a Hydroxynaphthoquinone with Anti-Pneumocystis carinii Activity: A Phase I Study in Human Immunodeficiency Virus (HIV)-Infected MenThe Journal of Infectious Diseases, 1991
- Effects of food on drug absorptionPharmacology & Therapeutics, 1989
- Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitroMolecular and Biochemical Parasitology, 1985
- The effect of oils on the lymphatic absorption of DDTJournal of Pharmacy and Pharmacology, 1982
- Real-time ultrasound. A new method for studying gall-bladder kineticsThe British Journal of Radiology, 1979
- Bioavailability of phenytoin in lipid containing dosage forms in ratsJournal of Pharmacy and Pharmacology, 1978
- Bioavailability of Micronized Griseofulvin from Corn Oil‐in‐Water Emulsion, Aqueous Suspension, and Commercial Tablet Dosage Forms in HumansJournal of Pharmaceutical Sciences, 1975
- Parameters Affecting Absorption of Griseofulvin in a Human Subject Using Urinary Metabolite Excretion DataJournal of Pharmaceutical Sciences, 1970
- INTRALUMINAL BILE-SALT DEFICIENCY IN THE PATHOGENESIS OF STEATORRHŒAThe Lancet, 1969